top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Mar 28, 2022
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds- -100% complete response (CR) observed in U.S. multi-center pilot trial of skin cancers at 12 weeks- -Targeted start of U.S. multi-center pivotal trial in skin cancers by the middle of 2022- JERUSALEM, March 28, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radia
- Mar 22, 2022
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
JERUSALEM, March 21, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through f
- Mar 8, 2022
Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022 JERUSALEM and WILMINGTON, Del., March 7, 2022 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (Nasdaq: HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the previously announced business combination (the "Business Combination"). The combined
bottom of page